Introgen Therapeutics’ Advexin® therapy combines the wild type p53 tumour suppressor gene with a non-replicating, nonintegrating adenoviral gene delivery system. Introgen originally licensed the p53 technology (along with other anticancer technology) from the M. D. Anderson Cancer Center (of the University of Texas) in July 1994.